Genitourinary cancers come in all shapes and sizes, and this year, ESMO2023 takes the research up a notch. Prostate cancer is centre stage, and you might ask why, as it boasts extraordinary overall survival and progression-free survival. The issue lies in the sequencing of therapies and how to make treatment durable and better tolerated for all. Third, immunotherapy is not ready for primetime in this cohort of patients, and the reasons are unclear. Not to be outdone, bladder cancer continues to make strides in patient care with a phase 1 study that may be lost in no-man land or could harbour a shift in trial design with antibody drug conjugates. Today, we discuss the following trials:

Articles discussed in this episode. Subscription may be required:

• Keynote 641 (Pembrolizumab + enzalutamide in the metastatic castrate-resistant prostate cancer sphere)
• https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2819%2930688-6/fulltext
• PSMAfore trial (LuPSMA in taxane naive patients)
• https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/639061
• MAGNITUDE Study (Niraparib and abiraterone)
• https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/639153
• The DAD study (sacituzumab govitecan (SG) plus enfortumab vedotin (EV)
• https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00563-6/fulltext

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

Hosted on Acast. See acast.com/privacy for more information.